Eleven randomized, controlled trials of antibiotic treatment versus placebo in patients with Campylobacter species infection were pooled in a meta-analysis. Antibiotic treatment shortened the duration of intestinal symptoms by 1.32 days (95% confidence interval, 0.64-1.99;
B R I E F R E P O R T
A Meta-Analysis on the Effects of Antibiotic Treatment on Duration of Symptoms Caused by Infection with Campylobacter Species double-blind, randomized, controlled clinical trials where antibiotic treatment Materials and methods. Our predefined inclusion criteria included only randomized, blinded, placebo-controlled clinical trials. Participants of all ages were included; they all suffered from diarrhea, and Campylobacter species was identified by stool culture for all. The clinical outcome measured was duration, in days, of diarrhea after the start of therapy. We also tried to measure clearance of Campylobacter species in stool samples after therapy; however, studies presented these data in different ways and seldom with any measure of variance of the results, thereby making a meta-analysis difficult to perform. These data are, therefore, compiled in a descriptive table.
We searched the Medline, Web of Science, Embase, Cochrane Central Register of Controlled Trials [9] , and ClinicalTrials.gov databases for studies to include in our analysis. Both free text word searches and searches using medical subject heading (MeSH) terms were performed; details of the search strategy are listed in the appendix. All citations in the studies retained for detailed evaluation were also checked. Publications published up to June 2006 were included.
We used the "weighted mean difference" method when pooling different datasets. Because not all articles reported variance (and/or SE) estimators, we calculated global (pooled) variances from all reported values to use in studies where no variance error was reported. We calculated 2 separate variances, one for the treatment groups and the other for the placebo groups. Denoted by , the sample size for study number k and by n k the variance reported for study number . The global 
The pooled variances were applied to a study of size by n k , to take the sample size into account. Unfortunately, 2 of the articles we analyzed contained calculation or printing errors. One or both of the SEs and P values reported in references [10] and [11] cannot be correct. We have used the reported SEs but have been unable to get information to determine whether these are correct.
Although all included studies were randomized, controlled trials, they differed in several aspects from each other (e.g., in age distribution, antibiotics administered, and time to first treatment dose). As a result, we considered that any observed difference between studies in treatment effect could not be confirmed to be an effect of sampling variation alone. Therefore, in addition to a fixed-effect meta-analysis, we also calculated a random-effect meta-analysis to allow for heterogeneity between studies. All statistical analyses were undertaken in R software, version 2.2.1, using the meta package [12] .
Results. Figure 1 summarizes the flow of identifying eligible clinical trials. Eleven randomized clinical trials were ultimately included in our meta-analysis [10, 11, [13] [14] [15] [16] [17] [18] [19] [20] [21] . These 11 trials included a total of 479 patients and had a mean study size of 43 subjects (range, 11-146 subjects) (table 1) . Against placebo, 6 of the studies tested the antibiotic erythromycin, 3 tested ciprofloxacin, and 3 tested norfloxacin. Four of the trials were strictly restricted to children and accounted for 19% of participants in this study (91 of 479).
The mean number of days with diarrhea before intervention was 3.5 (range, 0.8-5.6) in the treatment group and 3.7 (range, [14] ) was excluded from analysis of mean value because of lack of data. All studies except 1 had point estimates of the mean number of days of diarrhea after therapy in favor of antibiotic treatment compared with placebo. Our meta-analysis of the trials revealed a reduction in mean number of days of diarrhea with antibiotic treatment compared with placebo of 1.32 days (95% CI, 0.64-1.99 days;
) using a random effects model (figure 1) P ! .001 and 1.95 days (95% CI, 1.90-1.99 days;
) using a fixed P ! .001 effects model.
In table 2, we present a compilation of the mean number of days of excretion of Campylobacter species after either antimicrobial therapy or placebo. It is clear from the data that antibiotic therapy shortened the carrier state with Campylobacter species in human intestinal flora.
Discussion. Our meta-analysis confirms the findings of small randomized, controlled trials that are often cited in guidelines and reviews: that antibiotic treatment shortens the duration of diarrheal illness. Although the effect is evident, our data indicate a mean decrease in diarrheal illness of !2 days with antimicrobial treatment. Antibiotic treatment also shortened the excretion of Campylobacter species from feces. Unfortunately, the data do not allow us to quantify this effect in any robust way.
As can be seen in figure 2 , the effects of treatment show some variability, which indicates heterogeneity between studies. One such factor that differed between studies was the time interval from first symptoms to treatment. We tried to estimate the effect of duration of illness before therapy on the duration of diarrhea after therapy in a linear regression model. The results were nonsignificant ( ), as a result of too few P p .30 observations, and showed a mean decrease of 0.35 days per day of earlier treatment. By dividing the data into 2 groups-those treated within 3 days of illness and those who received treatment after у3 days or more had passed-we saw that the mean duration of diarrhea after therapy was 2.38 days in the first group and 4.11 days in the second group. One adverse effect of using antibiotics is the development of drug resistance. Campylobacter species are becoming increasingly resistant to quinolones and, to a lesser extent, macrolides, although the main driving force behind this seems to be the use of antibiotics in veterinary, and not human, medicine [22] . This may have clinical implications. First, one cannot be certain that quinolones generally work empirically, and it is certain that they do not in some parts of the world. With the increasing importance of travel-related Campylobacter species infection in the Western world [23] , the possibility of resistance must always be taken into account. The same is true in countries with an otherwise favorable resistance situation and imported foods. Second, even if our meta-analysis supports the effect of treatment, campylobacteriosis is self-limited in the majority of cases. If symptoms continue for a longer period of time, most patients will receive antibiotics. At the same time, however, antimicrobial therapy is probably most effective when administered early in the course of disease. This represents a clinical problem: to identify those persons in whom one could anticipate a severe infection and provide treatment to them as early as possible.
The treatment effect of antibiotics seems to be greater for enteric infections with Campylobacter species than for enteric infections with Salmonella species [24] . In Salmonella-associated gastroenteritis, prolonged carriage has been documented after use of antibiotics [15] . Antibiotics are, therefore, not recommended in cases of uncomplicated Salmonella enteric infection, but only in patient populations where the risk for invasive disease is elevated (e.g., infants, elderly persons, those with diseases priming for dissemination, and those who have undergone surgery that makes them vulnerable to metastatic seeding) [8] . In many high-income countries, Campylobacter species and Salmonella species, taken together, account for the vast majority of positive fecal cultures from patients who have infectious diarrhea. In the clinical situation, one sometimes has to consider antimicrobial therapy for community-acquired or traveller's diarrhea before the culture result of a fecal specimen is available, especially if the patient is at risk for invasive or severe disease. Our study supports the view that early antimicrobial treatment will shorten the duration of disease and the shedding of bacteria from stool. However, these benefits must be carefully weighed against the risk of furthering an already serious drug resistance situation or the risk of mismatch between antimicrobial susceptibility and given treatment at the individual level. Because Campylobacter species infection is generally a self-limiting disease, it is advisable to have a very restrictive attitude towards administration of antibiotics in uncomplicated cases that occur in non-high-risk patients.
